Brief Communication | Published:

Cytogenetics and molecular genetics

Characterization of an X-chromosome-linked telomere biology disorder in females with DKC1 mutation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Savage SA. Beginning at the ends: telomeres and human disease. F1000Res. 2018;7:524 https://doi.org/10.12688/f1000research.14068.1.

  2. 2.

    Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103:30–9.

  3. 3.

    Tukiainen T, Villani AC, Yen A, Rivas MA, Marshall JL, Satija R, et al. Landscape of X chromosome inactivation across human tissues. Nature. 2017;550:244–8.

  4. 4.

    Devriendt K, Matthijs G, Legius E, Schollen E, Blockmans D, Van Geet C, et al. Skewed X-chromosome inactivation in female carriers of dyskeratosis congenita. Am J Hum Genet. 1997;60:581–7.

  5. 5.

    Vulliamy TJ, Knight SW, Dokal I, Mason PJ. Skewed X-inactivation in carriers of X-linked dyskeratosis congenita. Blood. 1997;90:2213–6.

  6. 6.

    Trotta L, Norberg A, Taskinen M, Beziat V, Degerman S, Wartiovaara-Kautto U, et al. Diagnostics of rare disorders: whole-exome sequencing deciphering locus heterogeneity in telomere biology disorders. Orphanet J Rare Dis. (in press).

  7. 7.

    Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83:8604–10.

  8. 8.

    Xu J, Khincha PP, Giri N, Alter BP, Savage SA, Wong JM. Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations. Am J Hematol. 2016;91:1215–20.

  9. 9.

    Fernandez-Garcia I, Marcos T, Munoz-Barrutia A, Serrano D, Pio R, Montuenga LM, et al. Multiscale in situ analysis of the role of dyskerin in lung cancer cells. Integr Biol (Camb). 2013;5:402–13.

  10. 10.

    Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30:e47.

  11. 11.

    Vulliamy TJ, Kirwan MJ, Beswick R, Hossain U, Baqai C, Ratcliffe A, et al. Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations. PLoS ONE. 2011;6:e24383.

  12. 12.

    Alder JK, Hanumanthu VS, Strong MA, Dezern AE, Stanley SE, Takemoto CM, et al. Diagnostic utility of telomere length testing in a hospital-based setting. Proc Natl Acad Sci USA. 2018;115:E2358–65.

  13. 13.

    Norberg A, Rosen A, Raaschou-Jensen K, Kjeldsen L, Moilanen JS, Paulsson-Karlsson Y, et al. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet. 2018;26:858–67.

  14. 14.

    Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, et al. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia. 2018. https://doi.org/10.1038/s41375-018-0125-x.

Download references

Acknowledgements

This study was funded by grants from Academy of Finland (#274474, #312492, and #284538), Helsinki University Hospital Comprehensive Cancer Center Research Funding, Cancer Society of Finland, Signe and Ane Gyllenberg Foundation, and Väre Foundation for Pediatric Cancer Research. We are grateful to patients who participated and thus made this study possible. We thank Lotta Honkala, Pihla Siipola, and Annukka Ruokolainen for excellent technical assistance, and FIMM Technology Center for Sanger sequencing services.

Author contributions

EAMH and SP conducted the molecular laboratory experiments and analyzed the results (except the telomere analysis). AN and SD conducted the telomere length analysis and analyzed the results. KH-J and HV are responsible for the dermatological and odontological and oral mucosal examination and interpretation, respectively. OK and UW-K designed the study, participated in the analyses, and finalized the manuscript. All authors participated in drafting the manuscript and have read and approved the final manuscript.

Author information

Correspondence to Outi Kilpivaara or Ulla Wartiovaara-Kautto.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Supplementary Figures

Supplementary Table 1

Supplemental Material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2